Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Change In Receivables?

Hunan Er-Kang Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Hunan Er-Kang Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Hunan Er-Kang Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-20 Mil. It means Hunan Er-Kang Pharmaceutical Co's Accounts Receivable increased by ¥20 Mil from Dec. 2022 to Dec. 2023 .

Hunan Er-Kang Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥109 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Hunan Er-Kang Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 36.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hunan Er-Kang Pharmaceutical Co's liquidation value for the three months ended in Mar. 2024 was ¥281 Mil.

Hunan Er-Kang Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Change In Receivables Chart

Hunan Er-Kang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

85.61

-189.50

125.94

-9.11

-19.96

Hunan Er-Kang Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Hunan Er-Kang Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hunan Er-Kang Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	108.797	/	275.789	*	91
=	36.00

2. In Ben Graham's calculation of liquidation value, Hunan Er-Kang Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Hunan Er-Kang Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	535.187	-	685.98	+	0.75 * 108.797	+	0.5 * 701.295
=	281

Hunan Er-Kang Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Change In Receivables

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines